Oligonucleotide-siRNA Conjugate Targeting SOD1 Shows Favorable Safety in ALS Clinical Trial

A phase 1 clinical trial of an oligonucleotide–siRNA conjugate targeting the SOD1 gene demonstrated a favorable safety profile in six patients with SOD1-amyotrophic lateral sclerosis (ALS), according to a study published July 15, 2026, in Nature Medicine. The research indicates that repeated administration of the conjugate was well-tolerated by the small patient cohort.

The trial focused on a specific subset of ALS patients who possess mutations in the superoxide dismutase 1 (SOD1) gene.

The therapeutic approach tested in this study utilizes a conjugate consisting of an oligonucleotide and small interfering RNA (siRNA).

Safety outcomes of the SOD1-ALS conjugate trial

The primary objective of this phase 1 trial was to assess the safety and tolerability of the drug candidate. According to the Nature Medicine report, the repeated administration of the conjugate did not result in unexpected severe adverse events among the six participants.

The data from the six-patient group showed that the conjugate maintained a favorable safety profile throughout the dosing period.

Mechanism of siRNA in neurodegenerative treatment

The use of siRNA in this trial represents a targeted genetic approach to treating ALS.

Context of SOD1 mutations in ALS

Next steps for oligonucleotide-siRNA research

The results published on July 15, 2026, establish a safety baseline for this specific conjugate. However, because the trial only included six patients, the findings are not yet sufficient to prove clinical efficacy.